Table 3.
Overview of the effect of hyperbaric oxygen therapy on pain.
| Author (year) | Toxicity outcome measure | Scoring and grading | Measure | Baseline | End of HBOT | 3 months | 12 months | Significance |
|---|---|---|---|---|---|---|---|---|
| Feldmeier (1995) | – | – | – | – | – | – | – | |
| Carl (2001) | LENT-SOMA | Grade 1-4 | Median | HBOT: 3 Control: 3 |
HBOT: 0* Control: 3 |
– | – | S (p < 0.001) |
| Pritchard (2001) | SF-36 | Range 0-100 | Mean (SE) | HBOT: 41.5 (4.7) Control 59.2 (4.9) |
HBOT: 46.8 (5.8) Control: 60.4 (5.8) |
– | HBOT: 40.8 (4.6) Control: 54.2 (5.7) |
NR |
| Gothard (2004) | – | – | – | – | – | – | – | – |
| Teas (2004) | – | – | – | – | – | – | – | – |
| Gothard (2010) | – | – | – | – | – | – | – | – |
| Teguh (2016) | NRS | Score 0-10 | Median | 5 | 2* ≥1 point improvement in 81% of patients* |
– | – | S (p < 0.05) |
| EORTC-BR23 (breast pain) | Score 3–4 (severe problems) | % | 66.7 | 14.5* | – | – | S (p < 0.05) | |
| EORTC-BR23 (arm or shoulder pain) | Score 3–4 (severe problems) | % | 46.4 | 16.6* | – | – | S (p < 0.05) | |
| Spruijt (2020) | LENT-SOMA | Grade 1-4 | Median | 2 | 1* | 1* | 1* | S (p < 0.001) |
| VAS | Score 1-10 | Median | 6 | 3* | 2.5* | 2* | S (p < 0.001) | |
| Batenburg (2021) | EORTC QLQ-C30 | Range 0-100 | Mean | 43.4 | 30.5* | 29.7* | – | S (p < 0.001) |
| EORTC QLQ-BR23 (breast pain) | Grade 3–4 (severe problems) | % | 61.5 | 30.0 | – | – | NR | |
| Reduction in EORTC QLQ-BR23 breast pain score from grade 3–4 to 1-2 | Grade 1-4 | % | – | 58.8 | – | – | NR |
- = not applicable, * = significant when compared to baseline, NS = not significant, NR = significance not reported.